ETIOLOGY
Members of the cat family (Felidae) are the only known definitive hosts for the sexual stages of T. gondii and thus are the main reservoirs of infection. Cats become infected with T. gondii by carnivorism (1). After tissue cysts or oocysts are ingested by the cat, viable organisms are released and invade epithelial cells of the small intestine where they undergo an asexual followed by a sexual cycle and then form oocysts, which are excreted. The unsporulated oocyst takes 1 to 5 days after excretion to sporulate (become infective). Although cats shed oocysts for only 1 to 2 weeks, large numbers may be shed. Oocysts can survive in the environment for several months and are remarkably resistant to disinfectants, freezing, and drying, but are killed by heating to 70°C for 10 minutes.
Human infection may be acquired in several ways: A) ingestion of undercooked infected meat containing Toxoplasma cysts (2); B) ingestion of the oocyst from fecally contaminated hands or food (3); C) organ transplantation or blood transfusion; D) transplacental transmission; E) accidental inoculation of tachyzoites. The parasites form tissue cysts, most commonly in skeletal muscle, myocardium, and brain; these cysts may remain throughout the life of the host.
Toxoplasma gondii is an intracellular organism which infects warm blooded animals and humans. Toxoplasma is one of the most important sources of foodborne diseases and congenital infection. An estimated 1.5 billion people globally are infected, frequently with unknown lifelong health complications (86, 150). Toxoplasma is “Category B pathogenic agent” according the Center for Disease Control (CDC), and National Institute of Health (NIH). Following acute phase, the organisms dwell mainly in muscles and brain in cyst forms for the lifetime awaiting to be reactivated. Toxoplasma was discovered a century ago (1908) by Nicolle and Manceaux in an African rodent. Despite ever since ongoing investigations, yet there is no safe and effective therapy for congenital, chronic infection or a vaccine available to prevent toxoplasmosis.
Toxoplasma is an Apicomplexan protozoan parasite with sexual stage which takes place after oral infection in the intestinal epithelia of cats, as organisms replicate and mature to form resistant oocysts passed in the feces (68). Oocysts are formed by gametogony and sporogony. Cats usually become infected within 6 months of their life and pass unsporulated (immature) oocysts for about 1-2 weeks. Approximately millions of oocysts are excreted in the feces of cat 5 to 20 days after initial infection. Unsporulated oocysts become sporulated and mature in about 1 to 2 days in the moist soil to become infective forms of sporozoites. Sporozoites within protective oocyst are highly infectious when ingested and oocysts can remain viable in warm moist soil for over 1 year.
Humans and animals acquire systemic form of infection in asexual stage through consumption of contaminated animal products including fresh untreated milk, raw/undercooked meat and seafood or mature oocysts in water, fruits and vegetables (52, 54, 150). After sporozoites are released in the body they transform into tachyzoites, and attack every type of nucleated cells. Tachyzoites are the proliferative form in acute stage and reactivated stage of chronic infection. Bradyzoites are shaped in the dormant cysts during inactive or chronic stage of infection which replicate more slowly than the tachyzoites. Small pseudocysts are formed in tissues mainly during the early infection about a week after infection. Tissue cysts are formed within the host cells after acute stage and may contain thousands of bradyzoites which can persist as viable organisms as long as the host lives
Presence of the free tachyzoites establishes an active toxoplasmosis susceptible to available anti-Toxoplasma drugs. Tissue cysts are formed within the host cells which protect the bradyzoites against antimicrobial agent. The slow replicating bradyzoites are protected by the cyst wall against the action of the most available antimicrobial drugs. Bradyzoites are less susceptible to destruction by proteolytic enzymes than tachyzoites (52). Tissue cysts detection in biopsy specimens in addition to presence of inflammatory cells in the vicinity of the cysts determine patient with reactivation of dormantToxoplasma infection. Sporozoites are highly infectious when ingested. Oocysts can remain viable in environment for long period of time.
Toxoplasmosis Transmission
Toxoplasmosis is not acquired by casual direct contact from infected person with intact skin or airborne.
The common routes of transmission include:
a. Foodborne by contaminated water, milk, meat, unwashed fruits and vegetables or utensils.
b. Fetal Maternal (congenital).
c. Cat-man and animals: By handling contaminated soil, water and accidental fecal-oral infection.
d. Contaminated blood and organ transplant transmission.
e. Less common routes are “Sexual Transmission” by contaminated semen, and body fluid.
f. Accidental lab acquired infection by inoculation of contaminated material.
g. Breast feed transmission through contaminated milk with cysts and tachyzoites or environmental contamination of udders with oocysts.
Toxoplasma tachyzoites are secreted into milk in various farm animals. Contaminated milk transmission from farm animals has been reported by the consumption of unpasteurized milk from livestock as well as less common farm animals like camels and donkeys’ milk (41, 53, 187). Tachyzoites survive in the fresh milk and milk products in refrigeration for several days and can transmit the infection. Appropriate heating, freezing, or pasteurization can eliminate the infective forms for safe consumption.
EPIDEMIOLOGY
Toxoplasmosis is a global disease which burden humans and animals. The infection is usually asymptomatic and mild, while the prevalence of exposure increases with age and the lifestyle. There are conflicting reports regarding the decline of the seroprevalence rates of Toxoplasma infection in United States. It is estimated 22.5% of the U.S.A. population 12 years and older have been infected withToxoplasma (31). However, the infection report is on the rise in Europe (50% to 75%), Africa, South America, and Asia where the rate of infection is as high as 90% (181) possibly due to better diagnostic techniques and awareness. Toxoplasma infection is endemic in the farms and rural areas representing poverty and lack of appropriate hygiene. In the United States, the age-adjusted Toxoplasmaseroprevalence among people from 6 to 49 years old was reported to be 10.8% (95% confidence limits 9.6%, 11.9%), and for child-baring women 15 to 44 years old 11.0% (95% confident limit 9.5%, 12.4%) (101). Amongst immunocompetent individuals, the initial infection usually leads to a latent chronic infection that is effectively controlled by the host immune system. While, babies and immunosuppressed individuals are in a higher risk for active toxoplasmosis. The immunosuppressed ones include transplant recipients (bone marrow and solid organ transplants), patients with hematologic malignancy (e.g. Hodgkin's disease), and AIDS patients (70). The incidence of clinical manifestation of toxoplasmosis is uncommon among patients with CD4+ counts >200 cells/µl. Toxoplasmaencephalitis has been reported in 30% of AIDS patients with CD4+ counts of less than 100 cells/µl and who are not receiving effective anti-Toxoplasma prophylaxis or highly active antiretroviral therapy (HAART) (73). The incidence of Toxoplasma-induced encephalitis and the rate of mortality have significantly declined in United States and Europe where HAART and prophylactics for opportunistic infections including Toxoplasma are used and the guidelines for the use are appropriately implemented.
Humans and animals become infected by ingestion of contaminated food or hands with oocysts excreted from infected cats or consumption of undercooked meat containing cysts. Sporulated oocysts are transmitted to humans through soil during gardening, handling infected cat’s feces, contaminated fruits and vegetables or unpurified water (12, 20). Indeed, contaminated water is reported as a major source for infection during pregnancy in rural area (3). In the United States most farm animals including pig, lamb, goat, chicken and game animals were found infected to harbor Toxoplasma cysts
CLINICAL MANIFESTATIONS
Immunocompetent Patients
Acute toxoplasmosis is mostly subclinical and unnoticed in immune-intact humans and animals with flue like symptoms, fever, and cervical lymphadenopathy. The symptoms may last for a few weeks or up to months. In some individuals the clinical symptoms can be broad and mimic viral diseases such as infectious mononucleosis, cytomegalovirus and human herpes virus-6 with manifestation of sore throat, splenohepatomegaly, and presence of immature lymphocytes in blood stream. In addition, patients may develop symptoms of hepatitis, pancreatitis, splenitis, myocarditis, myositis and pain (31, 148,150, 151). Toxoplasmosis can be suspected in those patients with immunosuppressive conditions or unexplained syndromes in those who travelled to unsanitary and rural areas.Maternal and Fetal Toxoplasmosis
Pregnant women become infected by ingesting oocysts containing sporozoites contaminated food and water or consuming cysts with bradyzoites infected undercooked meat. The acute toxoplasmosis can be subclinical and diagnosed by routine serologic examinations. The primary infection acquired during pregnancy can be transmitted and infect the fetus via the placenta. However, normal women (immunocompetent) who were exposed to infection in past and prior pregnancy with low or stable anti-Toxoplasma IgG antibody titers are immune and mostly deliver healthy neonates.Additionally, transplacental transmission occurs by the reactivation of the chronic or latent infection caused by stressors due to pregnancy and other immunsuppressors. In any cases, whether oocysts or cysts are the origin of the infection, the organisms transform to active stage of tachyzoites and propagate to reach uterus. Tachyzoites then penetrate the transplacental blood barrier and invade the fetus to compromise the embryonic development. Toxoplasma infection rate of child-bearing women in Brazil is estimated 50% to 80%, and about 50% of children have antibodies titers. Also, 5 to 23 infants are found to be infected per 10,000 at birth in Brazil (54). Contaminated food and water with Toxoplasma oocysts are reported as the main source of human infection in North America (22, 130). The National Collaborative Chicago-based Congenital Toxoplasmosis (NCCCTS) reported that 78% of moms with infected infants had primary infection originated from oocysts while only half of these moms had direct contact with cats America (22, 130). While, educational hygienic programs are beneficial to the community, by itself cannot protect health and socioeconomic consequences related to the toxoplasmosis. Therefore, an effective and practical global cat vaccination program, implementation of serological testing of pregnant women, newborns, and those in high risk of infection followed by effective preventive and therapeutic regimens are necessary to eradicate toxoplasmosis.
Congenital Toxoplasmosis
Congenital disease was first reported in a 3 days old baby girl in New York, 1938 who developed seizure and eyes lesion and died after one month of birth (214). Congenital toxoplasmosis is mostly a subclinical infection in about 85% of the infants whose mothers have been treated for Toxoplasma during pregnancy (143). Theses proportions are influenced by factors such as, the time of maternal infection, treatment given to the mother, organism load and the genetics of the host and the strain ofToxoplasma. The incidence of fetal infection is estimated 2% if the maternal infection occur before week 10 and 90% in the last weeks of pregnancy. However, early maternal infection is reported to cause higher risk of disease and brain damage. Congenital toxoplasmosis manifests with spontaneous miscarriage and abortion, fetal growth retardation, encephalomyelitis, intracranial calcifications, hydrocephalus, neurological, mental illnesses, retinochoroiditis, visual and auditory inflammatory disorders, cardiovascular abnormalities (55, 130, 150, 152, 174), gastrointestinal complications and pain (57, 114, 148, 149, 150, 158). The severity of complications depends on the gestation period when the fetus is infected, and the earlier the infection the more severe the complications (55, 174). Those fetuses infected late in gestation may born normal, but develop symptoms of CNS and retinochoroiditis later in life and the new lesions may occur in untreated as well as treated children (55). Retrospective trials (2000–2011) reviled 18% (2206/12035) prevalence rate of anti-Toxoplasma antibody in pregnant women. Thirty eight per 10,000 of these women had acute infection and 5.8% transplacentally infected their neonates as reported in Argentina
Other factors involve are genetic tendency affecting immune response including HLA may influence clinical outcomes (99, 123). As pregnancy progresses, maternal immune system is modified to tolerate the growing semi-allogeneic fetus, at the same time to protect mom and offspring against pathogens. Therefore, pregnancy requires a complex balance in regulation of the immune system at the fetal maternal utero-embryonic border ensuring tolerance (Th2) of the fetus (142, 150). The HLA-G expression reprograms maternal immune response towards tolerance. Professional antigen presenting B cells can activate or silent T cells, to partake in regulation of the immune response. B cells are involved in humoral immune response leading to pre-eclampsia, during pregnancy
Spiramycin therapy can prevent maternal transmission of infection in infants, particularly when administered within 8 weeks of seroconversion (199). The proportion of infected newborns was 61% from untreated-infected mothers and 23% in the group receiving spiramycin treatment (36). Retinochoroiditis clinical cases can occur in up to 80% of the infants born with congenital toxoplasmosis cases with subclinical symptoms, particularly during puberty and adolescence (135, 213), which can be prevented by early diagnosis and treatment of the children (80, 207). Isolation of Toxoplasma from the placenta is associated with Toxoplasma infected infant. The proportion of infected babies depends on the early diagnosis and treatment given during pregnancy. Usually 90% of untreated-infected moms deliver infected babies, in contrast 25% of treated with spiramycin and 50% of those moms receiving spiramycin and the combined pyrimethamine plus sulfadiazine in alternating courses deliver seronegative infants (36).
Ocular Manifestation of Disease
Retinochoroiditis often occurs in congenital infection in neonates but it can also happen post parturition as acquired toxoplasmosis in immunocompetent children or adults (18, 61, 137). About 21% of adults in Southern Brazil were found infected. In immunosuppressed and immunodeficient individuals particularly AIDS patients ocular involvement may occur due to relapse of a previously-acquired infection. Patients, often develop multiple active, atypical, large atypical and bilateral retinal lesions (145). Many patients may develop ocular disease soon after Toxoplasma infection. From 205 patients (10-96 years old) tested for ocular Toxoplasmosis between 2004-2010 at Palo Alto Medical Foundation Toxoplasma Reference Laboratory, 11.7% were detected to have recent infection (100).Before the AIDS pandemic only 50 cases of toxoplasmosis were documented in immunosuppressed patients (121, 182). Then the number of diagnosed cases significantly increased to several thousands of cases afterward. Clinical presentation of toxoplasmosis in these patients varies, as a prolonged unexplained fever to visceral manifestations, with neurological and pulmonary lesions
In HIV and AIDS patients, the major findings are Toxoplasma-induced encephalitis, as well as ocular, pulmonary or disseminated disease (118, 119). In a French hospital database on HIV with 60,000 patients, the incidence changed from 29% in 1992 to 14% in 1995 and 2.6% in 1998. This decline in the number of patients with toxoplasmosis was due to the advancement of HAART in 1995 as well as other prophylactic compounds such as combined trimethoprim plus sulfamethoxazole. Patients with encephalitis may develop symptoms of headache, fever, and neurological symptoms, including dizziness, confusion, coma, motor defect, visual abnormalities, and seizures.
Immunosuppressed Patients
Patients with dormant toxoplasmosis who receive allogeneic hematopoietic stem cell transplants or those with graft versus host disease are at risk of severe or fatal toxoplasmosis by reactivation of their latent infection. Toxoplasmosis can be manifested with fever, pneumonia or brain cysts which should alert the healthcare staff of infection. Seronegative patients who received a seropositive donor organ are similarly at risk of toxoplasmosis.
Organ Transplantation, Blood Transfusion and Toxoplasmosis
Organ transplant patients with liver, lung, bone marrow, pancreas and kidney recipients are at risk for toxoplasmosis. This is as a result of immunosuppressive treatments and organ from infected donors or reactivated chronic infection followed with a high morbidity and mortality rate if not detected in early stages. Toxoplasmosis is considered as underestimated complication following hematopoietic stem cell transplantation and blood transfusion (195). It is commonly detected in autopsy or remains undetected due to the general and non-specific symptoms combined with lack of clinical awareness of healthcare personals (140). In Japan, while the incidence rate of toxoplasmosis in transplant patients is low (1.8%) but the mortality in infected patients reported to be very high (195). Toxoplasmosis is frequently difficult to diagnose and potentially fatal in kidney transplant recipients.
Women with renal disease who become pregnant are generally in a very high risk especially in those with chronic renal insufficiency, end-stage renal disease, dialysis patients and transplant recipients. Hypertension is the most common life-threatening problem in these moms. Transplant recipients are at risk for infections including Toxoplasma and can infect their fetus.
Renal disease patients have an increased risk for prematurity and intrauterine growth restriction. For women who conceive after starting dialysis, the probability of a surviving infant is reduced to 50% (89,90). Therefore, transplant recipients including allogeneic bone marrow and peripheral blood stem cell for malignant hematologic diseases and severe congenital immunodeficiency conditions need to be monitored for Toxoplasma as well as other opportunistic infections (90).
Mental Diseases and Toxoplasmosis
Toxoplasma attacks the central nervous system with adverse affect in brain neuro-structural development and pathological, as well as psycho-behavioral alteration, leading to mental retardation (11, 24, 211). More recently, maternal exposure or latentToxoplasma infection has been linked to a potential increased risk for autism and schizophrenic episodes and this hypothesis has received a great deal of scientific and media coverage (62). Toxoplasma can alter brain dopamine (59, 203). In a longitudinal trial, women with chronic toxoplasmosis had a high risk of self-harm and accidents (162). Another cross-sectional study indicated that Toxoplasma seropositive individuals had elevated risk of nonfatal suicidal violence (216).
Women with chronic toxoplasmosis have higher proportion to deliver infants with genetic or developmental disorders. For instance premature fetuses show slower rates of development in the first trimester as well as postnatal motor development in infants of moms with latent toxoplasmosis. In addition, these infants had a significant delayed in ability to control their head movements (p<0.05), due to decreased strength of embryonic quality control related to immunosuppression caused by infection in mothers. These defects may be due to severity of congenital toxoplasmosis, cognitive and developmental deficits or caused by the diarrheal malnutrition (103).
A 20 year retrospective trial with military personnel, university students, pregnant women and blood donors has shown even asymptomatic Toxoplasma infection can greatly affect humans (62). The infected subjects varied from controls in the characteristic behaviors suggesting Toxoplasma influences personality and increasing probability of traffic accidents of infected individuals. Dormant infection in mothers is associated with immunosuppression, and high prevalence to have children with Down syndrome or schizophrenia (62).
Another trail evaluated school children in rural area for seropositive and seronegative, developmental age, body mass, height, physical fitness, grades and the risk factors of infection like contact with house cats and consumption of undercooked meat products. The prevalence was 41% for children to have anti-Toxoplasma antibodies measured by IFAT and ELISA tests. The rate of infection was lower in boys (36%) than in girls (44%). The developmental age measures with electrophoretical mobility of nuclei and school performance was significantly lower for Toxoplasma infected girls compared to matched controls. Those boys who ate raw/undercooked meat products were most likely to be seropositive (134). Another observational study (2000-2012) from Nepal, declared congenital toxoplasmosis as second to malaria with highest parasitic burden of 9255 disability-adjusted life year of 95% (48).
Toxoplasmosis and Autoimmune Disease
While, etiological factors in the induction of autoimmune disease remain obscure a possible link with toxoplasmosis may exist. Immunosuppressants, and monoclonal antibodies such as anti-TNF are extensively used in the treatment of autoimmune diseases and organ transplantation may provoke acute toxoplasmosis in these patients. Sera of 1514 patients with 10 autoimmune diseases in Europe and Latin America and 437 controls investigated for the prevalence of auto-antibodies and anti-Toxoplasma antibodies IgG and IgM in serum (186). Anti-Toxoplasma antibody IgG was positive in 42% of patients versus 29% of controls (p<0.0001). Anti-Toxoplasma antibody IgM was more prevalent in patients with anti-phospholipid syndrome (p<0.01), systemic sclerosis (p<0.05) and inflammatory bowel disease (p<0.05), than in controls. Anti-Toxoplasma antibody IgG was associated with ANCA-associated vasculitides (p<0.01), anti-phospholipid syndrome (p<0.0001), autoimmune thyroid diseases (p<0.0001), systemic sclerosis (p<0.0001), and rheumatoid arthritis (p<0.0001). The findings support the notion that Toxoplasma may contribute to the pathogenesis of autoimmune disease (150, 152, 186). Chronic inflammatory bowel disease (IBD) is mainly Crohn’s disease and ulcerative colitis. Chronic inflammatory bowel disease is considered as an exaggerated immune response to gut microbiota, and toxins from gram negative lipopolysaccharid (LPS), bypassing the inflamed mucosa (23, 153, 154). Additionally, extensive use of immunosuppressive agents in IBD patients increases the possibility to develop opportunistic diseases and toxoplasmosis. The greatest risks of infections may relate to the combined use of immunomodulating agents rather than to individual drugs (57). Chronic inflammatory bowel disease patients treated with corticosteroids, azathioprine, methotrexate, cyclosporine, and TNF-blocking biological are susceptible to infections. Crohn’s patients are prone for gut abscess formation followed by infectious complications as well as toxoplasmosis. This alerts the physicians treating patients with IBD to be aware of the risk for infectious as well as of strategies to minimize these infectious complications in these patients (57, 150).
Severe colonic inflammatory response is observed in pregnancy model for toxoplasmosis, associated with significant shortening in colonic length, with infiltration of lymphocytes, and macrophages and microabscess formations in the cryptic structures in infected dams (148, 149, 157, 158). Chemically induction chronic inflammatory bowel disease model for ulcerative colitis utilizes oral administration of dextran sulfate sodium (DSS) for 3-16 cycles to induce chronic inflammation in the gut (153, 154) with increased gram negative gut microbiota. Colitis significantly increases colonic LPS (550-fold) in concentrations. Similarly, Toxoplasma induced ileitis with significant elevated ileal concentrations LPS (3,300-fold) P<0.01 (58). Sera from 119 chronic inflammatory bowel disease patients and 98 controls were assessed for anti-Toxoplasma antibody. Titer of anti-Toxoplasma was found higher in chronic inflammatory bowel disease patients than controls suggesting possible involvement ofToxoplasma in the pathogenesis of chronic inflammatory bowel disease, and specifically in Crohn’s disease (114). Finally, while inflammation is essential mechanism of defense against pathogens, excessive and chronic inflammatory response as in Toxoplasma infection severely damages the tissues and organs similar to as observed in patients with autoimmune diseases (30, 150). Toxoplasmainfection causes an exaggerated Th1 systemic inflammatory response which enhances pro-atherogenic effects (115, 170).
Toxoplasma and Sexual Attraction
Recent investigations reveal mind alteration and sexual attraction in Toxoplasma infected rats to seek cat’s urine odor, while normal rats fear and flight as innate survival defensive (91, 106, 150). Therefore, brain altered and fearless infected rodent is eaten by cats’ species (definitive host) to complete the organism’s sexual lifecycle. Toxoplasma impairs the limbic brain neurons responsible for instinct defensive behavior and judgment activity adjacent to limbic regions of sexual desire when exposed to cat’s odor (91).Toxoplasmosis is sexually transmitted to the partner by contaminated semen during natural mating. Also, artificial insemination of semen from infects animals’ results in vertical transmission with 80% embryonic growth disruption and abortion (4, 117, 209). In fact, sexual transmission with infected semen during natural mating as well as artificial insemination remains as a potential route for vertical transmission to progeny in humans. Additionally, pregnant women with latent infection have a higher risk of infants with genetic or developmental disorders such as premature and slow motor development. These defects may be linked to malnutrition due to diarrhea and gut disorders or congenital toxoplasmosis induced developmental deficits (103, 152).
LABORATORY AND RADIOLOGICAL DIAGNOSTICS
Toxoplasma infection is a serious health risk issue for the fetus and immunocompromised patients. Therefore, rapid and accurate diagnostic measures are required for possible preventions and available therapeutic modalities. Toxoplasma infection and toxoplasmosis can be confirmed by the use of various methodologies including serological tests, polymerase chain reaction (PCR), and histological exams, as well as isolating the organisms and imaging analysis. Diagnosis of toxoplasmosis is mainly based on the serological tests detecting anti-Toxoplasma-specific antibodies in the patients’ sera samples. Most of the commercial serological kits currently available are based on Toxoplasma lysate antigens (137). Lab tests are less reliable in the immunosuppressed patients which diagnosis performed in the context of the clinical development.Serologic Diagnosis for Toxoplasma Antibodies
The detection of Toxoplasma-specific IgM, IgG, IgA are to establish the infection in patients exposed to the organisms. Patients with negative IgG and IgM do not have serological evidence of prior exposure to the organism and are considered as uninfected; except for patients with organ transplant which serological tests alone are not reliable. Patients with positive IgG but negative IgM are possibly infected for several months or years. Positive or negative IgG and negative IgM serological tests results obtained in commercial laboratories are usually reliable (113, 171). Positive IgM test may indicate a recent acquired or an activated infection in the patients. In neonates a positive IgM test 5 days or a positive IgA after 10 days of birth confirms congenital toxoplasmosis.
Sabin-Feldman dye test, a complement-lysis-based assay with relative sensitivity and specificity to measure anti-Toxoplasma IgG antibodies is the international “gold standard” for diagnosis of toxoplasmosis (183). The Sabin-Feldman dye test is considered to be somehow more reliable than commercially available ELISA kits in some labs, but the test is time consuming and requires live organisms treated with each serum dilution to be analyzed under the microscope (38).
Available commercial kits require parasite antigen and have interassay variability. The recombinant Toxoplasma SAG1 antigen expressed in bacteria as inclusion bodies, and refolded in native form by dialysis has shown promising results. The antigen used in ELISA can detect IgG in saliva and sera with 100% sensitivity and specificity (32). In addition, the new multiplex, BioPlex® 2200 automated analyzer (Bio-Rad Laboratories, Hercules, CA) and ToRC IgG/IgM kit can detect anti-Toxoplasma antibodies in the same assay and is considered superior to Platelia IgG/IgM ELISA test (Bio-Rad Laboratories) or Toxo-Screen Direct Agglutination assay (bioMérieux, Lyon, France) with 91.3% specific and 97.8% sensitive to detect IgG and IgM, thus yielding more precise diagnosis of acute Toxoplasma infection (82).
Isolation of Toxoplasma
Detection of the organisms establishes an acute infection. Isolation can be done by tissue culture or mouse inoculation. Cell culture is more widely available, but mouse inoculation is more sensitive. Bradyzoites in cysts and free tachyzoites in infected tissue biopsies are detected using immunohistochemical staining, Giemsa and other direct staining methodologies.Immunohistochemical Staining (IHC)
IHC is a reliable technique for possible visualization of organisms in biopsies or sections. The paraffin-embedded sections are cut, deparaffinized with xylene, rehydrated in alcohol baths, washed in PBS with 0.1% bovine serum albumin (BSA), then quenched for endogenous peroxidase activity by incubating in 3% hydrogen peroxide in methanol 30 min, and blocked with rabbit serum (Dako #N1699) for 30 min. The sections are incubated with poly or monoclonal anti-Toxoplasma antibody, diluted 1:500 for 90 min and developed with DAB-Chromogen (DakoCarpenteria, CA) for about 5 min until signal developed and subsequently counterstained with hematoxylin then ammonia treated, dehydrated stepwise through alcohol, and cleared in xylene (148, 158). IHC detection of organisms proves infection, but negative does not rule out the disease.
Giemsa Staining
Polymerase Chain Reaction (PCR)
Pathology
Radiologic Examinations
Fetal Maternal Toxoplasmosis Diagnostics
Standard laboratory diagnosis of toxoplasmosis is based on the presence of IgM and IgG anti-Toxoplasma antibodies, and molecular technology is utilized as alternative tools to increase sensitivity (96). Typical infection is associated with high anti-Toxoplasma IgM antibody followed by a rise in IgG levels in 1 to 3 weeks after infection. However, atypical infection with IgG sero-conversion occurs in pregnancy without detectable IgM levels. These cases are very difficult to diagnose in congenital toxoplasmosis (72). The pregnant women with low or steady levels of IgG anti-Toxoplasma antibody have been previously exposed to the organism and fetus may remain safe. However, detection of IgM or elevation of IgG anti-Toxoplasma antibodies suggest a new acquired or reactivation of chronic/latent infection due to possible immunosuppression with a risk of infection for the fetus. Therefore, amniotic fluid exam can be performed to determine health status of the fetus and possible exposure to the infection. Toxoplasma-antibodies in infants during the first year of life present congenital toxoplasmosis.
In serious cases of neurological disorders including visual and auditory impairments, IgM and IgG antibodies combined with CSF polymerase chain reaction (PCR) is recommended to detect Toxoplasma DNA. Of 58 infants (0 to 180 days) born from infected moms, CSF PCR was positive in 46.5% and 100% negative in uninfected healthy infants. PCR was positive in 80% of those infants with hydrocephalus, 53% in cerebral calcifications and 60% of those with eye complications. Therefore, infants with neurological disorders, IgM and IgA antibodies combined with CSF PCR, are considered to yield a higher sensitivity for diagnosis of congenital toxoplasmosis when compared with each test alone (147).
Anti-Toxoplasma IgG and IgM with similar specificity and sensitivity are detected with the Vidas (bioMérieux), Architect (Abbott), and Liaison (DiaSorin) systems. The LIAISON system is a fully automated system based on chemiluminescence and antigen bound to magnetic microparticles. The Vidas system fits the needs of smaller laboratories with high specificity and a powerful avidity test in pregnant women and infants sera. A confirmatory serologic test is recommended to improve the rate of detection of congenital toxoplasmosis at 1 year of life (141, 164).
Additional serological tests to detect Toxoplasma specific IgG and IgM in blood samples are the indirect fluorescent antibody test (IFAT), microparticle enzyme immunoassay (MEIA) and enzyme-linked fluorescent assay (ELFA) used according the manufacturer’s instructions. The IgM sensitivity is reported 60% with specificity 100% except for IFAT with 92% and ELISA-IgA of 57% respectively (10). The molecular diagnostic include Western Blot analysis to detect anti-Toxoplasma IgM and IgA in infected infants (49). Cerebral toxoplasmosis is fatal if not treated and difficult to diagnose. Detection of anti-Toxoplasma IgM in CSF is reported as a reliable marker for cerebral Toxoplasmosis (96).
PATHOGENESIS
Tachyzoites trigger a strong immune response responsible for the clinical symptoms of toxoplasmosis during the acute or reactivation of the latent infection. In immunocompetent individuals free tachyzoites provoke a strong immune system and are killed by serial activation of complement associated antibodies, reactive oxygen and nitrogen radicals, osmotic fluctuations, and intracellular acidification. Humoral immune responses, IgG, IgM, and IgA are responsible for lysing extracellular tachyzoites. However, some tachyzoites attach cells and invade intracellular milieu and parasitophorous vacuole to avoid the innate and adaptive immune mechanisms. These tachyzoites transform into bradyzoites with distinct structure and slower metabolism which replicate to form the resistant tissue cysts. Tissue cysts primarily form in muscles, heart, brain, and retina, are responsible for the chronic infection. In immunocompetent individuals the cell-mediated immunity response including macrophages, natural killer cells, CD4+ T cells (Th1) and CD8+ T cells are responsible to control the propagation of the organisms (2, 142). Cytokines such as TNFα, IFNγ, IL-1, IL-2, IL-4, IL-6, IL-7, IL-12, IL-15 mediate protective immunity. Co-stimulatory molecules such as CD28 and CD40 ligand are critical for the regulation of IL-12 and IFNγ production in response to the parasite. It is possible that different cytokines production initiates the extent of the infection in individuals. Hence, Toxoplasma may specifically impact levels of circulating cytokines, and results in differences in the clinical severity of toxoplasmosis (163). Tissue-specific immune responses, such as that in the central nervous system are being currently elucidated.
Immunosuppression caused by T-cell mediated immunity impairment as in administration of anti-CD52 monoclonal antibody, in AIDS, allogeneic hematopoietic bone marrow and transplantation may lead to the transformation of bradyzoites to the rapid dividing tachyzoites and reactivation and dissemination of the toxoplasmosis. Tachyzoites cause significant pathology in severely immunocompromised individuals with as high as 100% mortality rate if untreated. While in the presence of intact innate, humoral and cellular immune responses the acute infection eventually transition into the life-lasting chronic and asymptomatic phase waiting for an opportunity to become activated.
TOXOPLASMA GENOTYPES
CURRENT AVAILABLE ANTI-TOXOPLASMA THERAPIES
Pyrimethamine (Daraprim)
Pyrimethamine should be administered in combination with other effective drugs as the efficacy is very limited. The possibility of relapses following discontinuation of the drug in immunosuppressed patients warrants prolonged duration of treatment following the acute phase of the infection. Pyrimethamine is metabolized in liver and its pharmacokinetics is not altered by renal insufficiency. The lack of correlation between serum concentrations and varying pharmacokinetics between patients suggest genetic differences in metabolizing the drug and monitoring serum levels of pyrimethamine can be useful in patients.
Oral administration daily is necessary treatment in acute infection. Pyrimethamine in immunocompetent adults at a daily dose of 25 mg (0.3 mg/kg) leads to serum concentrations of 0.9 to 1.7 µg/ml. In HIV patients a dose of 50 to 75 mg/day leads to serum concentrations of 1 to 4.5 µg/ml with peak levels at 3.3 hours (105). A minimal serum concentration of 3.0 µg/ml may be required to treat Toxoplasmaencephalitis in HIV infected patients (212). Serum concentration 4 h after a daily dose of 1 mg/kg in infants was 1.3 µg/ml which decreased to 0.7 µg/ml if was given every other day (131) which remained fairly stable during treatment period. Concentrations of pyrimethamine achieved in infants' sera with standard dosages had effective inhibitory effect in vitro on most virulent strains including the RH strain (131). CSF concentrations of pyrimethamine range 10 to 25 % of the serum in patients with leukemia or AIDS patients with Toxoplasma encephalitis (212). Half-life of the drug was 40 hours in brain tissue and 28 hours in serum, which implies that a dose of 50-100 mg every other day is convenient for prophylactic therapy in AIDS. Pyrimethamine may interact with other drugs including phenobarbital affecting hepatic enzymes and the drug metabolism can be altered in liver disease patients.
Anti-Toxoplasma activity of sulfonamides is by inhibiting dihydrofolate-synthetase enzyme essential in the purine pathway in Toxoplasma, while have minor cytotoxicty and side effects (1,122). Sulfadiazine is commonly prescribed while other sulfonamides, sulfapyrazine, sulfamerazine and sulfadimidine are also effective and can be used as trisulfapyrimidine combination (sulfadimidine, sulfamerazine and sulfadiazine).
Spiramycin
A clinical trial in pregnant women treated with a daily dose of 3 g, the maternal serum, cord blood and placenta tissue average concentrations were 1.9 µg/ml, 0.8 µg/ml and 6.2 µg/g respectively (74). The fetal-maternal ratio in sera was about 0.5 by the weeks 21-24 of pregnancy and 0.7 at birth (64). Administration of Spiramycin to infected pregnant women is associated with a significant decrease (60%) of the risk for placental and fetal infection (43) and maternal-fetal transmission (47). Spiramycin is rapidly adsorbed by sera, with elevated levels to persist in tissues and placenta. It is ineffective against cerebral toxoplasmosis in AIDS patients (112). Spiramycin application is specifically to protect fetus against acquired toxoplasmosis during pregnancy in a dose of 3 g/day oral route in 2 or 3 divided doses [206].
Clindamycin
Other Macrolides
Atovaquone
Atovaquone (administered orally as a suspension) combined with either pyrimethamine or sulfadiazine as treatment for acute disease for patients with Toxoplasma encephalitis has been shown to be effective, with 6-week response rates of 75% (21/28 patients) for atovaquone plus pyrimethamine and 82% (9/11) for atovaquone plus sulfadiazine. Thus, atovaquone plus pyrimethamine can be used as an alternative treatment for patients intolerant to sulfonamides, and atovaquone plus sulfadiazine for patients who are intolerant to pyrimethamine (34,107). In addition, combined atovaquone plus pyrimethamine or sulfadiazine are also effective in for Toxoplasma encephalitis in AIDS patients (34).
Trimethoprim, Trimetrexate, Piritrexime
Other Drugs
Immunomodulators
Combination Drugs
Combined pyrimethamine plus sulfadiazine with proven synergistic effect remains as basis treatment for human toxoplasmosis, but possible side effects including rash creates major obstacle for application. Pyrimethamine plus sulfadoxine can be used for prolong treatment and available in oral or parenteral route. In case of rash desensitization program is practiced (172). Combined pyrimethamine plus sulfadoxine has been shown with synergistic effect in murine toxoplasmosis (122), while 100% of organisms were eradicated when treated immediately and only 32% when delayed 72 hours after inoculation of organisms. Pyrimethamine plus sulfadoxine has severe side effects.
Other Combinations
THERAPEUTIC INDICATIONS
Acute Toxoplasmosis in Immunocompetent Patient
Acute Infection During Pregnancy
Application: Spiramycin is recommended for pregnant women suspected acquired the infection < 18 weeks of gestation and administered until delivery.
Spiramycin (PO) dose: 1g (3 million units)/8 hr or total: 3g (9 million units)/day
Alternatively pyrimethamine plus sulfadiazine and leucovorin is given to pregnant women in the late second and third trimesters to treat positive infected fetus by means of PCR for amniotic fluid or suspected with abnormal ultrasound after the 18 week of pregnancy following written consent and under close supervision (138, 139). Pyrimethamine plus sulfadiazine passes placental barrier and is recommended for women with acquired acute infection after 18 weeks of gestation. Due to the increased risk of maternal-fetal transmission of the organisms in late pregnancy indicated (180). Pyrimethamine 50 mg/day and sulfadiazine 3g/day is administered until delivery with hematological monitoring. Pyrimethamine plus sulfadiazine significantly reduce the rate of Toxoplasma isolation from the placenta and antibody synthesis of specific IgM and IgG titers in the neonate. Side effects include fetal injury. Trimethoprim plus sulfamethoxazole has been recommended as an alternative to treat congenital toxoplasmosis during pregnancy (45).
Recommendation: Pyrimethamine is teratogenic and should not be used in pregnancy before week 18.
Recommended for women suspected of having acquired the infection at ≥ 18 weeks of gestation; those with positive amniotic fluid PCR test or abnormal ultrasound suggestive of congenital toxoplasmosis, and who is over 18 weeks of gestation.
Application: Pyrimethamine: 50 mg/12 hr for 2 days followed by 50 mg daily (PO)
Sulfadiazine: 75 mg/kg (first dose) followed by 50 mg/kg every 12 hr (maximum 4 g/day) (PO)
Leucovorin (Folinic acid): 10-20 mg daily (during and for 1 wk after pyrimethamine therapy) (PO)
Congenital Toxoplasmosis
Pyrimethamine plus sulfadiazine is the standard treatment to prevent ocular symptoms. The Chicago Collaborative Treatment Trial recommendation requires continuous therapy for the first year of life in those children with possible infection (127). Acute retinochoroiditis has been shown to become subclinical within two weeks or less following the application of therapy and without visual loss in most treated patients (133). Most infants without hydrocephaly have normal IQ ranges versus half of those with hydrocephaly (127, 176, 197). About 75% of infants treated early after birth for toxoplasmosis, intracranial calcifications diminished or resolved by age 1 (160). While serologic titers appeared in 97.7% of the cases following discontinuation of the treatment, but this did not lead to an increased risk of ocular relapse (50). A clinical trial in 257 newborns from infected moms treated with spiramycin and pyrimethamine plus sulfadoxine in France, 24% were diagnosed with congenital infection. From these, 7% were predicted to be infected in the first, 24% in second, and 59% in third gestation period, respectively (17). Infected infants are required to be treated for 1 year.
Application: Pyrimethamine: 1 mg/kg /12 hr for 2 days, followed by 1 mg/kg/day for 2- 6 months, followed by 1 mg/kg three doses/week
Sulfadiazine: 50 mg/kg/12 hr
Leucovorin (Folinic acid): 10-20 mg three times/ week
Prednisone (CSF protein ≥ 1 g/dL for retinochoroiditis): 0.5 mg/kg/12 hr until CFS protein < 1 g/dL or symptoms resolve.
Treatment of older children with active disease continues 1-2 weeks after resolution of symptoms.
Pyrimethamine: 1-25 mg/kg every 12 hr for 2 days followed by 1-25 mg/kg per day
Sulfadiazine: 75 mg/kg (first dose) followed by 50 mg/kg every 12 hr
Leucovorin (Folinic acid): 10-20 mg three times weekly
Prednisone for retinochoroiditis: 0.5-20 mg/kg/12hr, rapid taper
Ocular Toxoplasmosis
Infection in Immunocompromised Patient
Infection in AIDS Patients
STANDARD OF CARE THERAPY
Acute Therapy
Trimethoprim plus sulfamethoxazole was reported in a small (77 patients) randomized trial to be effective and better tolerated than pyrimethamine plus sulfadiazine (201). No parenteral formulation of pyrimethamine exists for the patients who cannot take oral tablets. However, sulfamethoxazole is available in parenteral form. ICU patients and those with severe Toxoplasma encephalitis can receive parenteral trimethoprim plus sulfamethoxazole or oral pyrimethamine plus parenteral clindamycin.
Treatment is usually initiated upon assumption of Toxoplasma encephalitis, based on clinical symptoms of fever, neurological manifestations, seizers and the presence of brain lesions detected by CT scan or MRI. The diagnosis of Toxoplasma encephalitis is less likely in Toxoplasma seronegative patients (e.g. HIV+) with single lesion detected by MRI and/or patients who are on trimethoprim plus sulfamethoxazole prophylactic for Pneumocystis pneumonia (31, 120, 156).
Application: Pyrimethamine 50 mg/12 hr (2 days) followed by 25-50 mg daily
Leucovorin (Folinic acid) 10-50 mg/day (PO) continued 1 week after Pyrimethamine.
Sulfadiazine (PO) 75 mg/kg (first dose) followed by 50 mg/kg/12hr
Trimethoprim plus Sulfamethoxide 5-10 mg/kg/12 hr (PO or IV)
Maintenance Therapy
Alternative Therapeutic Regimens
Combined therapies with trimethoprim plus Sulfamethoxazole, Pyrimethamine plus Atovaquone or Ataovaquone plus Sulfadizine are also effective in AIDS patients with Toxoplasma encephalitis.
Combined Pyrimethamine plus Macrolides
Application: Pyrimethamine 50 mg/12 hr (2 days) followed by 25-50 mg daily
Leucovorin (Folinic acid) 10-50 mg/day (PO) plus pyrimethamine and continued 1 week after
Sulfadiazine 75 mg/kg (first dose) then 50 mg/kg/12 hr (PO)
1000 (<60 kg) to 1500 mg (>60 kg) every 6 hr
Or Clindamycin 300-1200 mg/6 hr (PO or IV)
Atovaquone 1500 mg/12 hr (PO)
Trimethoprim plus Sulfamethoxide 5-10 mg/kg/12 hr (PO or IV)
Pyrimethamine/folinic acid
Plus Clarithromycin 500 mg/12 hr (PO)
Or Dapsone 100 mg/d (PO)
Or Azithromycin 900-1200 mg/day(PO)
Adjuvant Therapy
Congenital Toxoplasmosis
Ocular Toxoplasmosis
AIDS
ENDPOINTS FOR MONITORING THERAPY
Monitoring of Adverse Events
Sulfonamides
Pyrimethamine plus Sulfonamides Combination therapy
Clindamycin
EXPERIMENTAL THERAPIES
Promising Experimental Compounds
Experimental Diclazuil, Atovaquone Monotherapy and Combination Therapy
While atovaquone protects against some aspects of gastrointestinal complications in experimental congenital toxoplasmosis in murine (158), diclazuril was superior to atovaquone in improving anemia, colonic length and hepatic complications against maternal toxoplasmosis (157). In addition, diclazuril plus atovaquone combination therapy exerted a unique synergistic effect against more severe fetal maternal toxoplasmosis and superior action to diclazuril or atovaquone monotherapy (148, 149). Diclazuril and diclazuril plus atovaquone warrant clinical trials in maternal congenital as well as in ocular and chronic toxoplasmosis. Finally, Diclazuril is anticipated to be used as a novel protective and preventive measure to eliminate the cycle of Toxoplasma infection in the definitive host, feline.
VACCINES
PREVENTIVE MEASURES
PROPHYLACTIC THERAPEUTIC AGENTS
Congenital Toxoplasmosis
The date of maternal infection is of important relevance to transmission. Immunocompetent moms normally have no risk if had exposed before conception. However, infection during pregnancy period has a high risk of transmission and congenital toxoplasmosis as the later the infection date during pregnancy, the higher the risk of transmission (47). Among women with seroconversion, the incidence of maternal-fetal transmission increases as the pregnancy progresses. Spiramycin is most effective if given as prophylactic and before infection has reached the embryo. In pregnant women treated with spiramycin, the incidence of fetal transmission increases from 2%, if maternal infection happen during 3 to 10 weeks of gestation, to over 30% when after 31 weeks (87). The incidence reaches 90% in infections during the last two weeks of pregnancy. In addition, the earlier the maternal infection occurs during pregnancy, the higher the risk of brain injury in the fetus. It is indicated that maternal infection after week 26 may become more subclinical.
Prophylactic spiramycin is administered as 3g per day, oral route, and should be given immediately after detection of infection during pregnancy to reduce the possible transmission to the embryo (47, 65,66, 208) or to reduce the severity of the disease in possibly infected infant (67). A negative PCR in amniotic fluid requires spiramycin administration to prevent or delay maternal fetal transmission. Administration of azithromycin in 500 mg/day for 3 times/ week for 1 to 4 weeks showed Concentrations in placental tissue were 10 fold higher in placenta than in amniotic fluid or maternal or cord blood (194).
Ocular Toxoplasmosis
AIDS
Toxoplasma Encephalitis in Seropositive Patients
Primary Prophylactic Therapies
Toxoplasma Prophylaxis and Highly Active Antiretroviral Therapy
Prophylaxis for Other Immunosuppressed Hosts
Those organ recipients, who are seronegative for Toxoplasma and transplanted organ from seropositive for Toxoplasma donor, are recommended to receive pyrimethamine 50 mg/day to markedly reduce the risk of toxoplasmosis (88, 121, 215). Trimethoprim plus sulfamethoxazole is a possible alternative which has not been extensively assessed. In bone-marrow recipients, the risk of toxoplasmosis is the highest in seropositive patients who receive bone-marrow from a donor who is seronegative for Toxoplasma (44, 63, 126, 146). The pyrimethamine plus sulfadoxine or trimethoprim plus sulfamethoxazole combinations have been recommended for children. In these transplant patients, the duration of chemoprophylaxis depends upon the duration of the immunosuppressive therapy. Limited information is available for other causes of immunosuppression (19). It has been suggested that patients with immune cell defects or those on long term corticosteroid therapy, should be considered for prophylaxis of toxoplasmosis when the CD4 cell count reaches less than 100/µl. Pyrimethamine or trimethoprim plus sulfamethoxazole should be recommended for the duration of the immune defect persists.
Additional Information
Chicago, U.S.A National Collaborative Treatment Trial Study (NCCTS), telephone number (773) 834-4152.
The Toxoplasma Serology Laboratory (Dr Jack Remington), the Palo Alto Medical Foundation, Palo Alto, CA. Website: http://www.pamf.org/serology/; Phone number: 650 853 4828]
Centers for Disease Control and Prevention, Atlanta, GA, 1-800-CDC-INFO, weekday 8am-8pm EST. cdc.gov/parasite/toxoplasmosis.
Spiramycin (Rhone-Poulenc Pharmaceuticals) is not FDA approved, and available via individual investigator IND for treatment of pregnant women with toxoplasmosis. Information on the Spiramycin program is available by the Division of Special Pathogens and Immunologic Drug products at FDA at (301) 827-2335.
FDA Adverse Events Report
Erroneous result or any adverse event from an anti-Toxoplasma commercial test kit resulting in death or serious illness must be reported.
Voluntary report is encouraged directly to MedWatch, the FDA's voluntary reporting program. Telephone at (800) FDA-1088, by FAX at (800) FDA-0178,
Mail to: MedWatch, Food and Drug Administration, Rockville, MD 20857
沒有留言:
張貼留言